A Non-interventional, Real-world Study on the Adjuvant Treatment of Chinese EGFR-positive Stage IA NSCLC Patients With High-risk Factors Using Third-generation EGFR-TKIs.

NCT07686185 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

500

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer
Adjuvant Therapy

Interventions

DRUG: Third-generation EGFR-TKI

Sponsor

First Affiliated Hospital of Guangxi Medical University